Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Group CoSHTDF -15.53%74 EV-to-Revenue is 0.26 as of Sep. 14, 2026, which is 13% above its 10-year median of 0.23. GuruFocus rates SHTDF with a GF Score™ of 74/100 and a GF Value™ of $2.81 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 123 Medical Distribution companies, Sinopharm Group Co ranks better than 76.42% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sinopharm Group Co's enterprise value is $21,153 Mil.
Sinopharm Group Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $82,787 Mil. Therefore, Sinopharm Group Co's EV-to-Revenue for today is 0.26.
The historical rank and industry rank for Sinopharm Group Co's EV-to-Revenue or its related term are showing as below:
SHTDF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.17 Med: 0.23 Max: 0.48
Current: 0.26
During the past 13 years, the highest EV-to-Revenue of Sinopharm Group Co was 0.48. The lowest was 0.17. And the median was 0.23.
SHTDF's EV-to-Revenue is ranked better than 76.42% of 123
companies
in the Medical Distribution industry
Industry Median: 0.6
vs SHTDF: 0.26
Sinopharm Group Co's share price for today is $1.816.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2025 was $26.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co EV-to-Revenue Related Terms
Sinopharm Group Co EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co EV-to-Revenue vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's EV-to-Revenue falls into.
Sinopharm Group Co's current Enterprise Value is $21,153 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Group Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $82,787 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDF) has a EV-to-Revenue of 0.26 as of Sep. 14, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Sinopharm Group Co and its competitors. This is 13% above median its historical median of 0.23. Over the past decade, Sinopharm Group Co's EV-to-Revenue has ranged from 0.17 to 0.48. According to the industry distribution chart, Sinopharm Group Co ranks #29 out of 123 companies in the Medical Distribution industry, placing it in the top 23.6%.
Is Sinopharm Group Co's EV-to-Revenue too high?
Sinopharm Group Co's current EV-to-Revenue of 0.26 is 13% above median its 10-year median of 0.23. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 0.48. The Medical Distribution industry median EV-to-Revenue is 0.60. Sinopharm Group Co's value of 0.26 is 56.7% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #29 out of 123 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's EV-to-Revenue compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #29 out of 123 companies for EV-to-Revenue. This places Sinopharm Group Co in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-Revenue is 0.60. Sinopharm Group Co's value of 0.26 is 56.7% below this benchmark. Historically, Sinopharm Group Co's own EV-to-Revenue has ranged from 0.17 to 0.48 over the past decade. While the company's 10-year median is 0.23 vs. the industry median of 0.60, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Medical Distribution company?
The median EV-to-Revenue among Medical Distribution companies is 0.60, based on 123 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current EV-to-Revenue of 0.26 is 56.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median EV-to-Revenue is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current EV-to-Revenue is 0.26, which is 13% above median its own 10-year median of 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.81, compared to a current price of $1.82 — trading 35.4% below its estimated fair value. The current EV-to-Revenue is 0.26, which is 13% above median its 10-year median of 0.23 and 56.7% below the Medical Distribution industry median of 0.60. Sinopharm Group Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current EV-to-Revenue is 0.26 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $1.82 is trading 35.4% below its estimated GF Value™ of $2.81.
GuruFocus considers Sinopharm Group Co to be Significantly Undervalued.
Key valuation signals for SHTDF:
EV-to-Revenue: 0.26 (13% above median its 10-year median of 0.23)
GF Value™: $2.81 vs. price of $1.82 (35.4% below fair value)
Industry Position: 56.7% below the Medical Distribution median (#29 of 123)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
74GF Score
Get the complete analysis for SHTDF
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
